Product Information
Ibrutinib is an inhibitor of tyrosine kinases, including BTK, ABL1, and PDGFR. It is a racemic mixture of ibrutinib enantiomers that has been shown to be effective against lymphocytic leukemia. Ibrutinib has minimal toxicity in humans and has been shown to be well-tolerated with few side effects. Ibrutinib binds to the active site of BTK, blocking the attachment of ATP and leading to inhibition of downstream signaling pathways that are involved in cell proliferation and survival. The drug also inhibits the activity of other tyrosine kinases such as ABL1 and PDGFR.
Chemical properties
Technical inquiry about: 3D-LMB56387 Ibrutinib Racemate
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.
